NEUROendocrine SENSor for Sudden Unexpected Death in Epilepsy (SUDEP) prediction and prevention

NEUROSENSE proposes a novel and visionary technology resulting from the demonstration of the upstream role of arousal in sudden unexpected death in epilepsy (SUDEP). SUDEP is a societal challenge for which there is neither prediction nor prevention. Research in the field has long been refining classic concepts based on cardiac, respiratory, and autonomic nervous systems impairment. Our vision is different and based on the neuroendocrine processes of epileptic seizures and arousal, which are expected to be impaired in SUDEP. The NEUROSENSE project will develop the first SUDEP Medical Device (SMD) prototype supported by artificial intelligence (AI) to anticipate life-threatening seizures and trigger automatic emergency drug administration to prevent SUDEP. This represents the very first viable solution for the societal-friendly management of epilepsy-derived mortality, thus enabling the prevention of SUDEP worldwide. This will be achieved through the combination of expertise and innovative ideas in epilepsy and SUDEP, biosensors for medical devices, animal models of epilepsy and SUDEP, and mathematical modeling. To tackle the objectives of the NEUROSENSE project, a multidisciplinary group of European leading experts in key technological areas will ensure that the complete chain of value is enclosed in a multifaceted analysis. The high-risk character of this joint science and technology research is offset by the multidisciplinary nature of the Consortium, by strong and extensive preliminary data, and by the high socioeconomic gain resulting from its successful execution. Based on the new SMD technology, we will build a diverse portfolio of future projects that will result in long-term benefits for people with epilepsy, their families, the economy, and society.


Project title: NEUROendocrine SENSor for Sudden Unexpected Death in Epilepsy (SUDEP) prediction and prevention

Project acronym: NEUROSENSE

Project number: 101047131



Type of action: HORIZON-EIC

Service: EISMEA/E/01

Project duration: June 2022 – May 2025 (48 months)

Total cost: € 3,739,723.75

Requested EC funding: € 3,739,723.75

Partners: I3S – Instituto de Investigação e Inovação em Saúde da Universidade do Porto, FILADELFIA, BIOSTRIKE, Karolinska Institutet, Centre National de la Recherche Scientifique (CNRS), Kinetikos – Driven Solutions, Centre Hospitalier Universitaire Vaudois (CHUV)